MetaCap

Iambic Therapeutics (IAM) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iambic Therapeutics is the larger company by market cap ($621.4 million vs $596.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IAM-30.67%SRZN+13.52%
+34%-8%-50%
Oct 15, 20261 yearNov 20, 2026
IAM-44.94%SRZN+21.42%
+39%-11%-62%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IAM versus SRZN key metrics
MetricIAMSRZN
Share price$13.11$28.46
Market cap$621.42M$596.40M
1-day change-8.06%-7.21%
YTD return—+25.93%
1-year return—+115.61%
5-year return—-78.97%
EPS (TTM)$-2.69$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.48M
Revenue growth (YoY)—-67.37%
Net income (latest FY)—$-242.03M
Operating margin—-1210.58%
Net margin—-6960.77%
52-week high$25.00$37.83
52-week low$9.60$12.79
Distance from 52-week high-47.56%-24.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+107.86%+123.12%
Average volume714.92K537.16K
Shares outstanding47.40M20.96M
Employees17144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

IAM vs SRZN FAQ

Which is bigger, Iambic Therapeutics or Surrozen?

Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $596.40M for Surrozen (SRZN).

Are Iambic Therapeutics and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons